10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy) due to a recent upward trend in earnings estimates; the consensus estimate for the fiscal year ending December 2025 has increased 16% over the past three months, with an expected EPS of -$1.15. The Zacks rating system, which factors in earnings estimate revisions, has historically shown that stocks in the top 20% have the potential for market-beating returns. This upgrade suggests a positive outlook for TXG's stock price in the near term.

Analysis

10x Genomics (TXG) has received a significant upgrade to a Zacks Rank #2 (Buy), primarily driven by an upward trend in its earnings estimates, a factor Zacks identifies as a powerful force impacting stock prices. This improved outlook is quantified by the Zacks Consensus Estimate for the fiscal year ending December 2025, which, despite projecting a loss of $1.15 per share, represents a notable 24.3% year-over-year improvement. Furthermore, this consensus estimate has increased by 16% over the past three months, indicating growing analyst confidence in the company's earnings trajectory. According to Zacks, such positive revisions in earnings estimates often signal an improvement in a company's underlying business fundamentals, which can attract institutional investors and subsequently drive share prices higher. The placement of TXG within the top 20% of Zacks-covered stocks, due to this Rank #2, suggests a superior earnings estimate revision profile and implies potential for market-beating returns in the near term, based on the historical performance of Zacks' top-ranked stocks.

Key Decisions for Investors

• Investors should consider the Zacks Rank #2 upgrade for 10x Genomics as a positive indicator, underpinned by strengthening earnings estimate revisions and suggesting potential near-term stock appreciation.
• The 16% increase in the Zacks Consensus Estimate for FY2025 over the past three months warrants attention, reflecting an improving operational outlook for TXG.
• While the earnings trajectory is positive with a 24.3% YoY improvement anticipated for FY2025, the projected EPS of -$1.15 indicates the company is still expected to be loss-making, a risk factor that should be weighed against the growth prospects.